83602-38-4

Basic information

• Product Name: Ethyl (S)-nipecotate L-tartrate
• Synonyms: (S)-ETHYL NIPECOTATE-D-TARTRATE;(S)-ETHYL NIPECOTATE-L-TARTRATE;(S)-(-)-ETHYL NIPECOTATE (+)-TARTRATE;(S)-NIPECOTIC ACID ETHYL ESTER (2S,3S)-TARTRATE;(S)-NIPECOTIC ACID ETHYL ESTER D-TARTRATE;(S)-3-PIPERIDINECARBOXYLIC ACID ETHYL ESTER D-TARTRATE;ETHYL (S)-NIPECOTATE D-TARTRATE;ETHYL-(S)-NIPECOTATE-L-TARTRATE
• CAS NO: 83602-38-4
• Molecular Formula: C12H21NO8
• Molecular Weight: 307.3
• Mol File: 83602-38-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 156°C
• Boiling Point: 504.6ºC at 760 mmHg
• Flash Point: 259ºC
• Appearance: /
• Vapor Pressure: 2.69E-12mmHg at 25°C
• Refractive Index: -10.3 ° (C=5, H2O)
• Water Solubility: Soluble in water
• CAS DataBase Reference: Ethyl (S)-nipecotate L-tartrate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl (S)-nipecotate L-tartrate(83602-38-4)
• EPA Substance Registry System: Ethyl (S)-nipecotate L-tartrate(83602-38-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36-36/37/38
• Safety Statements: 24/25-36-26
• Hazardous Substances Data: 83602-38-4(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

Ethyl (S)-nipecotate L-tartrate

InChI:InChI=1/C8H15NO2.C4H6O6/c1-2-11-8(10)7-4-3-5-9-6-7;5-1(3(7)8)2(6)4(9)10/h7,9H,2-6H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)/t7-;/m0./s1

Upstream product

• 147-71-7 D-tartaric acid 
• 71962-74-8 Ethyl nipecotate 
• 253177-06-9 3-((2S,3R)-2-Benzyloxycarbonyl-4-oxo-azetidin-3-ylmethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 87-69-4 L-Tartaric acid 
• 498-95-3 (R)-nipecotic acid 
• 25137-01-3 (R)-ethyl nipecotate 

Downstream Products

• 140695-84-7 tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 668270-12-0 Linagliptin 
• 334618-23-4 3-(R)-aminopiperidine dihydrochloride 
• 145821-58-5 ethyl (R)-1-<4,4-bis(3-methyl-2-thienyl)-3-butenyl>-3-piperidinecarboxylate 

Relevant articles and documents

Synthetic method for (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine

The invention discloses a synthetic method for (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine. The method comprises the following four steps: synthesizing ethyl 3-piperidinecarboxylate (compoundII), synthesizing ethyl (R)-nipecotate-L-tartarate (compound III), synthesizing ethyl (R)-N-Boc-3-piperidinecarboxylate (compound IV) and synthesizing the (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine (compound V); and the method comprises the following special steps: synthesizing the compound II by using 3-piperidinecarboxylic acid (compound I) as a raw material through chloroacylation andethanol esterification; performing a salt formation reaction to form the compound III; adding a Boc anhydride and performing a reaction to obtain the compound IV; and finally performing sodium borohydride reduction to obtain the compound V. The method provided by the invention has the advantages of mild reaction conditions, environmental friendliness, simple operation steps, better reproducibilityand high practicability, and is suitable for industrial mass production of the (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine.

FARNESYL PROTEIN TRANSFERASE INHIBITORS

Disclosed are compounds of formula (1.0), wherein R represents a cyclic moiety to which is bound an imodazolylalkyl group; R represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.

N-[(R)-1-[3-(4-piperidyl)propionyl]-3-piperidylcarbonyl]-2(S)-acetylamino-β-alanine trihydrate, compositions thereof, and methods for its use

The trihydrates of β-alanine of the formula Are disclosed. Also method of antogonizing glycoprotein IIb/IIIa activity using these compounds is also disclosed.